Rep. Courtney and Rep. Houchin Introduce the Hidden Fee Disclosure Act of 2025
The Hidden Fee Disclosure Act of 2025 is currently in the early stages of the legislative process. It was recently sent to the House Committee on Education and Workforce for review. The bill is actively moving forward as it waits for the committee to discuss its next steps.
This bill has support from both parties and addresses high healthcare costs. However, large insurance companies and drug benefit managers often lobby against these types of rules.
Department of Labor employees would need to develop new rulemaking and enforce the expanded disclosure requirements. The bill explicitly requires the Secretary of Labor to issue rules within one year. However, this is standard agency implementation work, and the broader federal workforce is not meaningfully targeted by the bill.
Referred to the House Committee on Education and Workforce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
The legislation would insert significant transparency into the pharmaceutical supply chain by clarifying that PBMs and TPAs are required to disclose all direct and indirect compensation they receive as part of servicing a group health plan.
The Hidden Fee Disclosure Act (H.R. 4508) would attempt to address PBM transparency and loopholes identified in the No Surprises Act. It would prohibit PBMs and insurers from working with drug manufacturers if they cannot hold up their transparency requirements.
Document Type
Congressional Bill
Official Title
Hidden Fee Disclosure Act of 2025
Analysis generated by AI. Always verify with official sources.